search
Back to results

Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy (PANther)

Primary Purpose

ADHD

Status
Completed
Phase
Not Applicable
Locations
Netherlands
Study Type
Interventional
Intervention
Placebo EEG Neurofeedback
EEG-Neurofeedback
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ADHD focused on measuring ADHD, Children, EEG-Neurofeedback

Eligibility Criteria

8 Years - 15 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis ADHD, classified by the (Diagnostic and Statistical Manual of Mental Disorders, 2000)
  • Age between 8 and 15
  • A full scale IQ of more than 80
  • Psychopharmaca- naïve or -free, or using a stable dosage of psychostimulants or atomoxetine but still with room for improvement (defined by an average score of more than 1 on ADHD-DSM-IV rating scale).
  • Deviant EEG of more than 1.5 standard deviation compared to the database

Exclusion criteria:

  • Currently intensive (i.e. weekly) individual or group psychotherapy
  • Regular use of medication other than psychostimulants or atomoxetine
  • Diagnosis of one or more of the following comorbid psychiatric disorders:
  • Major depression
  • Bipolar disorder
  • Psychotic disorder
  • Chronically motor tic disorder or Gilles de la Tourette
  • Conduct disorder
  • Autism spectrum disorders
  • Eating disorders
  • Neurological disorders (e.g. epilepsy) currently or in the past
  • Cardiovascular disease currently or in the past
  • Participation in another clinical trial simultaneously
  • EEG-neurofeedback training in the past
  • Use of alcohol or drugs

Sites / Locations

  • FC Donders Centre for Cognitive Neuroimaging
  • Karakter Nijmegen

Arms of the Study

Arm 1

Arm 2

Arm Type

Placebo Comparator

Experimental

Arm Label

Placebo group

NF group

Arm Description

This group will receive no real EEG-Neurofeedback.

This group will receive real EEG-Neurofeedback

Outcomes

Primary Outcome Measures

ADHD criteria according to the DSM-IV-TR rated by the investigator.

Secondary Outcome Measures

side-effects by Score on the adapted Pittsburgh side effects rating scale

Full Information

First Posted
July 28, 2008
Last Updated
March 7, 2013
Sponsor
Radboud University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT00723684
Brief Title
Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy
Acronym
PANther
Official Title
ADHD and EEG-neurofeedback. A Single-blind Randomized Placebo-controlled Treatment Study.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
July 2012 (Actual)
Study Completion Date
February 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Radboud University Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Background: Electroencephalography (EEG)-neurofeedback has been shown to offer therapeutic benefits to patients with ADHD in several mostly uncontrolled studies with relatively small sample sizes. It is unknown how EEG-neurofeedback affects brain functioning and exerts therapeutic effects in ADHD. This study is designed to examine the efficacy and safety of EEG-neurofeedback in a scientific rigorously way and to study the underlying neurobiological mechanisms of EEG-neurofeedback. Objectives: To investigate the efficacy of EEG-neurofeedback in reducing behavioral symptoms of ADHD. To investigate whether EEG-neurofeedback is able to improve neurocognitive functioning. To investigate whether EEG-neurofeedback is able to improve neural functioning. Study design: Double-blind randomized placebo-controlled treatment study.Study population: 120 subjects with ADHD (age 8-15, IQ of 80 or more). Intervention: 60 subjects with ADHD receive 30 sessions EEG-neurofeedback, and 60 subjects with ADHD receive placebo EEG-neurofeedback. Main study parameter: ADHD-DSM-IV rating scale, rated by the investigator. Hypothesis: The hypothesis is EEG-Neurofeedback can reduce symptoms of ADHD.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ADHD
Keywords
ADHD, Children, EEG-Neurofeedback

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
63 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
This group will receive no real EEG-Neurofeedback.
Arm Title
NF group
Arm Type
Experimental
Arm Description
This group will receive real EEG-Neurofeedback
Intervention Type
Other
Intervention Name(s)
Placebo EEG Neurofeedback
Intervention Description
The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress). In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects.
Intervention Type
Other
Intervention Name(s)
EEG-Neurofeedback
Intervention Description
The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
Primary Outcome Measure Information:
Title
ADHD criteria according to the DSM-IV-TR rated by the investigator.
Time Frame
before, after 10, 20, 30 sessions and after half a year
Secondary Outcome Measure Information:
Title
side-effects by Score on the adapted Pittsburgh side effects rating scale
Time Frame
before, after 10, 20, 30 sessions

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
15 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis ADHD, classified by the (Diagnostic and Statistical Manual of Mental Disorders, 2000) Age between 8 and 15 A full scale IQ of more than 80 Psychopharmaca- naïve or -free, or using a stable dosage of psychostimulants or atomoxetine but still with room for improvement (defined by an average score of more than 1 on ADHD-DSM-IV rating scale). Deviant EEG of more than 1.5 standard deviation compared to the database Exclusion criteria: Currently intensive (i.e. weekly) individual or group psychotherapy Regular use of medication other than psychostimulants or atomoxetine Diagnosis of one or more of the following comorbid psychiatric disorders: Major depression Bipolar disorder Psychotic disorder Chronically motor tic disorder or Gilles de la Tourette Conduct disorder Autism spectrum disorders Eating disorders Neurological disorders (e.g. epilepsy) currently or in the past Cardiovascular disease currently or in the past Participation in another clinical trial simultaneously EEG-neurofeedback training in the past Use of alcohol or drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
J.K. Buitelaar, Professor
Organizational Affiliation
UMC St. Radboud and Karakter
Official's Role
Principal Investigator
Facility Information:
Facility Name
FC Donders Centre for Cognitive Neuroimaging
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6500 HB
Country
Netherlands
Facility Name
Karakter Nijmegen
City
Nijmegen
State/Province
Gelderland
ZIP/Postal Code
6525 GC
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
24168522
Citation
Vollebregt MA, van Dongen-Boomsma M, Buitelaar JK, Slaats-Willemse D. Does EEG-neurofeedback improve neurocognitive functioning in children with attention-deficit/hyperactivity disorder? A systematic review and a double-blind placebo-controlled study. J Child Psychol Psychiatry. 2014 May;55(5):460-72. doi: 10.1111/jcpp.12143. Epub 2013 Oct 30. Erratum In: J Child Psychol Psychiatry. 2014 Aug;55(8):954-5. J Child Psychol Psychiatry. 2014 Aug;55(8):954-955.
Results Reference
derived
PubMed Identifier
24021501
Citation
van Dongen-Boomsma M, Vollebregt MA, Slaats-Willemse D, Buitelaar JK. A randomized placebo-controlled trial of electroencephalographic (EEG) neurofeedback in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2013 Aug;74(8):821-7. doi: 10.4088/JCP.12m08321.
Results Reference
derived

Learn more about this trial

Project Attention Deficit Hyperactivity Disorder (ADHD) and Electroencephalography (EEG)-Neurofeedback THERapy

We'll reach out to this number within 24 hrs